Vanguard Group Inc. raised its position in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 8.8% during the first quarter, Holdings Channel reports. The institutional investor owned 1,564,170 shares of the medical research company’s stock after buying an additional 126,807 shares during the period. Vanguard Group Inc.’s holdings in Genomic Health were worth $49,256,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of GHDX. Columbia Wanger Asset Management LLC raised its position in shares of Genomic Health by 26.1% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,607,649 shares of the medical research company’s stock worth $50,625,000 after buying an additional 332,311 shares during the last quarter. Norges Bank purchased a new position in shares of Genomic Health during the fourth quarter worth $4,546,000. Tributary Capital Management LLC raised its position in shares of Genomic Health by 24.3% in the first quarter. Tributary Capital Management LLC now owns 294,962 shares of the medical research company’s stock worth $9,288,000 after buying an additional 57,591 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Genomic Health by 10.0% in the first quarter. Loomis Sayles & Co. L P now owns 584,515 shares of the medical research company’s stock worth $18,406,000 after buying an additional 53,344 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd purchased a new position in shares of Genomic Health during the first quarter worth $845,000. 89.53% of the stock is currently owned by institutional investors and hedge funds.

Genomic Health, Inc. (NASDAQ GHDX) traded up 1.40% on Friday, reaching $30.34. The company had a trading volume of 3,508 shares. The company’s 50-day moving average price is $32.31 and its 200 day moving average price is $31.11. Genomic Health, Inc. has a 1-year low of $25.66 and a 1-year high of $33.97. The firm’s market capitalization is $1.05 billion.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. The business had revenue of $85.50 million during the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.18) EPS. On average, equities analysts forecast that Genomic Health, Inc. will post $0.01 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/genomic-health-inc-ghdx-position-boosted-by-vanguard-group-inc/1471987.html.

A number of research analysts have recently weighed in on GHDX shares. Piper Jaffray Companies restated a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. Jefferies Group LLC restated a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a research report on Monday, June 12th. Raymond James Financial, Inc. restated a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $32.43.

In other Genomic Health news, Director Fred E. Cohen sold 16,500 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $29.88, for a total value of $493,020.00. Following the completion of the sale, the director now owns 74,145 shares in the company, valued at approximately $2,215,452.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Phillip G. Febbo sold 3,174 shares of the stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total transaction of $106,551.18. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,642 shares of company stock valued at $2,342,466. 46.20% of the stock is owned by insiders.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.